Dissociation between titer of anti-ganglioside antibody and severity of symptoms in a case of Guillain-Barré syndrome with treatment-related fluctuation.
Since plasma exchange (PE) and intravenous immunoglobulin (i.v.Ig) have been widely used in treatment for Guillain-Barré syndrome (GBS), early relapse and treatment-related fluctuation have been a potential problem, but little is known about the mechanism of relapse and fluctuation. We describe a patient who had GBS with treatment-related fluctuation. A 37-year-old Japanese man exhibited acute distal-dominant weakness in upper limbs after upper respiratory infection. His cranial nerve system was normal and muscle weakness was limited to upper limbs. Anti-GT1a IgG was strongly positive and anti-GQ1b IgG was also detected in his serum. Muscle weakness responded well to double-filtration plasmapheresis (DFPP) followed by i.v.Ig, but relapsed 45 days after the initial treatment. Although repeated treatments were effective, the patient showed additional minor deterioration twice. Motor nerve conduction velocities (MCVs) corresponded to the muscle weakness, but elevated level of cerebrospinal fluid (CSF) protein remained and anti-ganglioside antibody titers steadily decreased throughout the clinical course. These findings indicate that the clinical fluctuation was not due to changes in the production of anti-ganglioside antibodies but presumably to the transient beneficial effects of DFPP/i.v.Ig and the outlasting inflammatory response in peripheral nerves.
Inoue
Nami
N
First Department of Internal Medicine, University of Tokushima School of Medicine, 3 Kuramoto-cho, Tokushima, Tokushima 770-8503, Japan.
Kunishige
Makoto
M
Yoshida
Sumiko
S
Oshima
Yasushi
Y
Ohnishi
Yoshiaki
Y
Kuroda
Yasuhiro
Y
Asano
Atsuko
A
Yoshino
Hiide
H
Matsumoto
Toshio
T
Mitsui
Takao
T
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000906:Antibodies / Q000276:immunology*; D002556:Cerebrospinal Fluid Proteins / Q000378:metabolism; D003131:Combined Modality Therapy; D005732:Gangliosides / Q000145:classification / Q000276:immunology* / Q000378:metabolism; D020275:Guillain-Barre Syndrome / Q000276:immunology* / Q000628:therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D018908:Muscle Weakness / Q000503:physiopathology / Q000628:therapy; D009431:Neural Conduction / Q000502:physiology; D010951:Plasma Exchange / Q000379:methods; D010956:Plasmapheresis / Q000379:methods; D011239:Prednisolone / Q000627:therapeutic use; D012008:Recurrence; D034941:Upper Extremity / Q000503:physiopathology / Q000821:virology
D000893:Anti-Inflammatory Agents; D000906:Antibodies; D002556:Cerebrospinal Fluid Proteins; D005732:Gangliosides; D016756:Immunoglobulins, Intravenous; D011239:Prednisolone